SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-031568
Filing Date
2023-09-05
Accepted
2023-09-05 08:00:14
Documents
13
Period of Report
2023-08-29
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43742
  Complete submission text file 0001493152-23-031568.txt   262831

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE aneb-20230829.xsd EX-101.SCH 3257
3 XBRL DEFINITION FILE aneb-20230829_def.xml EX-101.DEF 26188
4 XBRL LABEL FILE aneb-20230829_lab.xml EX-101.LAB 35952
5 XBRL PRESENTATION FILE aneb-20230829_pre.xml EX-101.PRE 24846
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 4710
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 231234171
SIC: 2834 Pharmaceutical Preparations